CSF EULAR 2023 axSpA Highlights
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>EULAR</strong> <strong>2023</strong><br />
Congress Preview<br />
<strong>axSpA</strong><br />
Faculty Introduction<br />
Dear Colleagues,<br />
Welcome to this year’s selection of <strong>EULAR</strong> abstracts on <strong>axSpA</strong> and my ‘<strong>Highlights</strong>’. We have selected a variety of<br />
abstracts that cover a range of key topics in the management of axial spondyloarthritis.<br />
<strong>EULAR</strong> opens on Wednesday with the Abstract Opening Plenary session, where Mary Lucy Marques discusses the<br />
latest data on diagnosis in <strong>axSpA</strong> (OP0005). Wednesday also features a wide variety of interesting oral presentations in<br />
the Clinical aspects and Treatment of <strong>axSpA</strong>: effects and predictors of effects session. Victoria Navarro-Compán presents<br />
the ASAS Consensus Definition of Early Axial Spondyloarthritis (OP0055). This is followed by insightful presentations from<br />
Xenofon Baraliakos (OP0059) and Uta Kiltz (OP0058) on radiographic progression and Secukinumab real world data, as<br />
well as another talk by Mary Lucy Marques presenting more data from the SPACE cohort (OP0054).<br />
Thursday sees a number of interesting posters in the Disease mechanisms in spondylarthritis session. Our highlights<br />
include Fabian Proft presenting on the relationship between complement and radiographic progression (POS0043) and<br />
Matilda Morin presenting on childhood infections and perinatal factors as risk factors for <strong>axSpA</strong> (POS0045). There is also<br />
a fascinating presentation by Anna Moltó (POS0675). Thursday also features an interesting oral presentation by Marco<br />
Garrido-Cumbrera on the regional differences in the clinical phenotypes of <strong>axSpA</strong> (OP0187).<br />
Friday features more great <strong>axSpA</strong> related posters. This includes the latest data on a number of key therapeutics, from<br />
bimekizumab (POS1103, POS1107, POS0246) and upadacitinib (POS0250, POS1122), to tofacitinib (POS1116), and<br />
secukinumab (POS1115, POS1123). There is also a discussion on predicting successful tapering of biologics in patients<br />
with inflammatory arthritis by Line Uhrenholt (POS0254), and considerations on pain by Peter Rouse (POS0207-HPR).<br />
Pain is once again a topic on Saturday. There are two presentations on the topic, one discussing sex differences in regard<br />
to experienced pain (POS0365) the other neuropathic and neuroplastic pain components (POS0299). Long term data is<br />
presented for the impact of NSAIDs on the incidence of major cardiovascular events (POS0301).<br />
Finally, this year’s <strong>EULAR</strong> features several important symposia. This includes the <strong>CSF</strong>’s The “Case” for JAK Inhibitors, in<br />
which the faculty will discuss the optimisation of JAK inhibitor therapies. Truly, this promises to be an insightful discussion<br />
we don’t think you should miss. Additionally, we have highlighted a selection of other symposiums at the end of this<br />
brochure which we believe are not to be missed.<br />
As always, thank you for your continued support. We hope you have a fantastic time at <strong>EULAR</strong> <strong>2023</strong>!<br />
Kind regards<br />
Sofia Ramiro<br />
Ps. Make sure you get all the insights from this <strong>EULAR</strong> by downloading our other highlights brochures, and if you want to<br />
see the top picks for Lupus head on over to www.lupus-forum.com where you’ll find the top <strong>EULAR</strong> picks and their top<br />
abstracts in the field of lupus therapeutics.<br />
Register for FREE content at<br />
www.cytokinesignalling.com<br />
Follow us at:<br />
Cytokine Signalling Forum<br />
SPONSORSHIP AND UNRESTRICTED<br />
EDUCATIONAL GRANTS FROM<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE
KEY:<br />
H <strong>Highlights</strong> SCIENTIFIC SESSION ORAL SESSION POSTER SESSION<br />
Key Presentations<br />
Wednesday, 31 May <strong>2023</strong><br />
Thursday, 01 June <strong>2023</strong><br />
16:30–<br />
18:00<br />
OP0005<br />
16:30–<br />
18:00<br />
OP0054<br />
OP0055<br />
OP0056<br />
OP0057<br />
OP0058<br />
OP0059<br />
ABSTRACT OPENING PLENARY<br />
Chairs: Caroline Ospelt and Marta Mosca<br />
Can Axial Spondyloarthritis Unequivocally<br />
be Diagnosed by Rheumatologists in<br />
Patients with Chronic Back Pain Of Less<br />
Than Two Years Duration? Main Result of the<br />
Spondyloarthritis Caught Early (Space) Cohort<br />
Mary Lucy Marques<br />
CLINICAL ASPECTS AND TREATMENT<br />
OF AXSPA: EFFECTS AND PREDICTORS<br />
OF EFFECTS<br />
Chairs: Astrid van Tubergen and Alexandre Sepriano<br />
The Yield of Repeated Assessments in<br />
Chronic Back Pain Patients Suspected of<br />
Early Axial Spondyloarthritis: Two-Year Data<br />
From the Spondyloarthritis Caught Early<br />
(SPACE) Cohort<br />
Mary Lucy Marques<br />
ASAS consensus definition of early axial<br />
spondyloarthritis<br />
Victoria Navarro-Compán<br />
Sensitivity to change of structural lesions in early<br />
axial spondyloarthritis after 10 years of follow up.<br />
Data from DESIR cohort<br />
Clementina López-Medina<br />
Factors associated with achieving remission in<br />
patients with early peripheral spondyloarthritis:<br />
10-Year results from the German Spondyloarthritis<br />
Inception Cohort (GESPIC)<br />
Murat Torgutalp<br />
Prediction of low disease activity in patients with<br />
ankylosing spondylitis treated with secukinumab in<br />
real world – data from the German AQUILA study<br />
Uta Kiltz<br />
Effect of secukinumab versus adalimumab H<br />
biosimilar on radiographic progression in<br />
patients with radiographic axial spondyloarthritis:<br />
a randomised phase IIIb study<br />
Xenofon Baraliakos<br />
H<br />
H<br />
H<br />
11:15–<br />
12:00<br />
09:30–<br />
10:30<br />
POS0675<br />
12:00–<br />
13:30<br />
POS0043<br />
POS0045<br />
13:30–<br />
14:45<br />
OP0187<br />
AXIAL AND PERIPHERAL<br />
SPONDYLOARTHRITIS<br />
Chairs: Floris A. van Gaalen and Helena Marzo-Ortega<br />
Management of axial and peripheral<br />
spondyloarthritis in <strong>2023</strong><br />
Désirée van der Heijde<br />
POSTER VIEW 2<br />
Low rate of switching from nr-<strong>axSpA</strong> to<br />
r-<strong>axSpA</strong> after 10 years of follow up in early<br />
axial spondyloarthritis. Data from DESIR cohort<br />
Anna Moltó<br />
DISEASE MECHANISMS IN<br />
SPONDYLOARTHRITIS<br />
Chairs: Felicie Costantino and Francesco Ciccia<br />
Complement in radiographic <strong>axSpA</strong> – Biomarkers<br />
of radiographic progression? Post hoc analysis from<br />
CONSUL, a longitudinal multi-center randomized<br />
controlled trial cohort of <strong>axSpA</strong>-patients with a high risk<br />
of structural progression initiating treatment with TNF-I<br />
Clara Elbæk Mistegaard<br />
Childhood infections and perinatal factors as risk<br />
factors for ankylosing spondylitis – results from a<br />
nationwide case-control study<br />
Matilda Morin<br />
SPONDYLOARTHRITIS ACROSS THE AGES<br />
Chairs: Jordi Anton and Xenofon Baraliakos<br />
Regional Differences in Clinical Phenotype of Axial<br />
Spondyloarthritis. Results from the International Map<br />
of Axial Spondyloarthritis (IMAS)<br />
Marco Garrido-Cumbrera<br />
Friday, 02 June <strong>2023</strong><br />
09:30–<br />
10:30<br />
POS1103<br />
POSTER VIEW 4<br />
Bimekizumab maintained improvements<br />
in efficacy endpoints and had a consistent<br />
safety profile through 52 weeks in patients<br />
with non-radiographic and radiographic axial<br />
spondyloarthritis: results from two parallel<br />
phase 3 studies<br />
Xenofon Baraliakos<br />
H<br />
H
KEY:<br />
H <strong>Highlights</strong> SCIENTIFIC SESSION ORAL SESSION POSTER SESSION<br />
POS1104<br />
POS1107<br />
POS1108<br />
POS1109<br />
POS1111<br />
POS1115<br />
POS1116<br />
POS1120<br />
POS1122<br />
POS1123<br />
Bimekizumab maintained stringent clinical<br />
responses through week 52 in patients with axial<br />
spondyloarthritis: results from the phase 3 studies<br />
BE MOBILE 1 and BE MOBILE 2<br />
Fabian Proft<br />
Bimekizumab achieved sustained<br />
improvements in efficacy outcomes in<br />
patients with axial spondyloarthritis, regardless<br />
of prior TNF inhibitor treatment: week 52<br />
pooled results from two phase 3 studies<br />
Marina Magrey<br />
Efficacy of upadacitinib in patients with<br />
non-radiographic axial spondyloarthritis in<br />
early versus established disease<br />
Victoria Navarro-Compán<br />
Putative role of the histidine and tryptophan<br />
biochemical pathways in the mode of action of<br />
upadacitinib in patients with ankylosing spondylitis<br />
Walter P Maksymowych<br />
Treatment with upadacitinib results in the inhibition<br />
of a broad range of potentially pathogenic pathways<br />
in nr-axspa and bDMARD-IR as patients: proteomic<br />
analysis from the SELECT-AXIS 2 Phase 3 studies<br />
Walter P Maksymowych<br />
Effect of secukinumab versus adalimumab<br />
biosimilar on radiographic progression<br />
in patients with radiographic axial<br />
spondyloarthritis: subgroup analyses<br />
by baseline syndesmophytes and c-reactive<br />
protein status<br />
Xenofon Baraliakos<br />
Time to improvement of pain, morning<br />
stiffness and disease activity in patients with<br />
ankylosing spondylitis treated with tofacitinib<br />
Victoria Navarro-Compán<br />
Impact of baseline crp level on secukinumab (sec)<br />
retention in axial spondyloarthritis (axspa):<br />
results of the French retrospective study FORSYA<br />
Daniel Wendling<br />
Efficacy and safety of upadacitinib in<br />
patients with active ankylosing spondylitis<br />
and an inadequate response to biologic<br />
DMARD therapy: one-year results from a<br />
phase 3 study<br />
Xenofon Baraliakos<br />
Impact of the time of initiation and line of biologic<br />
therapy on the retention rate of Secukinumab<br />
(SECU) in axial spondyloarthritis (axspa). Data from<br />
the French multicenter retrospective FORSYA study<br />
Maxime Dougados<br />
H<br />
H<br />
H<br />
H<br />
12:00–<br />
13:30<br />
POS0246<br />
POS0247<br />
POS0250<br />
POS0254<br />
EVERYTHING YOU NEED TO KNOW ABOUT<br />
MANAGING IN AXSPA<br />
Chair: Philippe Carron<br />
Bimekizumab reduced mri inflammatory<br />
lesions in patients with axial spondyloarthritis:<br />
week 52 Results from the BE MOBILE 1 and<br />
BE MOBILE 2 phase 3 studies<br />
Xenofon Baraliakos<br />
Resolution of enthesitis and peripheral arthritis with<br />
bimekizumab in patients with axial spodyloarthritis:<br />
week 52 results from the BE MOBILE 1 and BE<br />
MOBILE 2 Phase 3 studies<br />
Sofia Ramiro<br />
Placebo-controlled efficacy and safety of<br />
upadacitinib through one year in patients<br />
with non-radiographic axial spondyloarthritis<br />
Filip van den Bosch<br />
Predicting Successful Tapering of Biologics in<br />
Patients with Inflammatory Arthritis: Secondary<br />
Analyses from the BIODOPT Trial<br />
Line Uhrenholt<br />
Saturday, 03 June <strong>2023</strong><br />
10:00–<br />
11:30<br />
POS0299<br />
POS0301<br />
10:00–<br />
11:30<br />
POS0347<br />
10:00–<br />
11:30<br />
POS0365<br />
CLINICAL ASPECTS OF SPONDYLOARTHRITIS<br />
Chairs: Denis Poddubnyy and Fabian Proft<br />
Neuropathic and neuroplastic pain components<br />
determine the presence of residual symptoms<br />
in patients with axial spondyloarthritis receiving<br />
biological disease-modifying anti-rheumatic drugs<br />
Fares Al Mohamad<br />
Impact of NSAIDs on 8-year incidence of<br />
major cardiovascular events in patients<br />
with ankylosing spondylitis<br />
Olivier Fakih<br />
BEYOND THE CRYSTAL BALL<br />
Chair: Casper Webers<br />
Determinants of patient and physician global<br />
assessment of disease activity in spondyloarthritis<br />
Catarina Dantas Soares<br />
IMPACT OF SEX ON DISEASE<br />
PATHOGENESIS AND OUTCOME<br />
Chairs: Irene van der Horst-Bruinsma and<br />
Loreto Carmona<br />
Sex Differences concerning Experienced Pain in<br />
Patients with Axial Spondyloarthritis<br />
Yvonne van der Kraan<br />
H<br />
H<br />
H
KEY:<br />
H <strong>Highlights</strong> SCIENTIFIC SESSION ORAL SESSION POSTER SESSION<br />
Satellite Symposia<br />
WEDNESDAY, 31 MAY <strong>2023</strong><br />
18:30–<br />
19:45<br />
18:30–<br />
19:45<br />
Why Benefit: Risk Assessment Should Drive<br />
Individualized Treatment Decisions<br />
Sponsor: AbbVie Chair: Kimme Hyrich<br />
Raising the Bar: Optimizing Outcomes in<br />
Spondylarthritis<br />
Sponsor: UCB Chair: Helena Marzo-Ortega<br />
THURSDAY, 01 JUNE <strong>2023</strong><br />
08:15–<br />
09:30<br />
08:15–<br />
09:30<br />
17:30–<br />
18:45<br />
17:30–<br />
18:45<br />
17:30–<br />
18:45<br />
17:30–<br />
18:45<br />
Finding the Right Treatment for the Right Patient:<br />
What Similarities and Key Differences Among RA,<br />
PsA and AxSpA Determine Treatment Decisions<br />
Sponsor: Lilly Chair: Roberto Caporali<br />
Getting to the Root of PsA and <strong>axSpA</strong><br />
Sponsor: Novartis Chair: Ennio Lubrano<br />
Connections Between the Gut, Joint and Spine:<br />
Evidence and Experience with JAK Inhibitors<br />
Sponsor: Pfizer Chair: Sofia Ramiro<br />
Infliximab IV to SC: Mainstay Therapy in Rheumatology<br />
Sponsor: Celltrion Chair: Roberto Giacomelli<br />
Healthcare<br />
The Time is NOW! Aiming for Higher Treatment<br />
Targets in PsA and AxSpA<br />
Sponsor: UCB Chair: Francesco Ciccia<br />
SpA on the Runway – A Front Row Seat for a Closer<br />
Look at the Latest Trends<br />
Sponsor: AbbVie Chair: Filip van den Bosc<br />
FRIDAY, 02 JUNE <strong>2023</strong><br />
08:15–<br />
09:30<br />
17:30–<br />
18:45<br />
The Great Debate: Force of Habit vs. Innovative<br />
Approach in the Management of Inflammatory<br />
Rheumatic Diseases<br />
Sponsor: Lilly Chair: Carlo Selmi<br />
The “Case” for JAK Inhibitors<br />
Sponsor: Lilly Chair: Elena Nikiphorou<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Change language